Aslan Pharmaceuticals appoints eminent cancer researcher to chair scientific advisory board
pharmafile | January 28, 2016 | Appointment | Research and Development | Aslan, Professor Sir David Lane
Aslan Pharmaceuticals has appointed four global cancer experts to its new scientific advisory board.
The Board will be chaired by the eminent scientist Professor Sir David Lane, who is renowned for his contributions to cancer research, including the discovery of the p53 tumour suppressor protein.
He was most recently awarded the 2012 Cancer Research UK lifetime achievement award. He is concurrently chief scientist of the Agency for Science, Technology and Research (A*STAR), scientific director of Ludwig Cancer Research and chairman of Chugai Pharmabody Research.
Aslan is a Singapore-based biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types.
Other members of the board are world-leading experts in understanding the etiology, disease mechanism and the treatment of gastrointestinal cancers:
- Professor Patrick Tan, Professor at the Duke-NUS graduate medical school and associate director of genomic medicine at the Genome Institute of Singapore
- Dr Yong Wei Peng, associate director (research) and senior consultant of National University Cancer Institute Singapore (NCIS). He also leads the therapeutic arm of the Singapore Gastric Cancer Consortium
- Dr Matthew Ng, a medical oncologist specialising in GI cancers and new cancer drug development at National Cancer Centre Singapore (NCCS). He is currently principal investigator of various Phase I trials and Phase II and III gastrointestinal cancer trials
Dr Bertil Lindmark, chief scientific cfficer of Aslan Pharmaceuticals, says: “We are delighted and honoured to collaborate with a group of prominent leaders in Asia cancer research as part of Aslan’s scientific advisory board. Each of our scientific advisory board members brings a wealth of experience that supports our strategy and decision-making process.
“We are especially fortunate to have Professor Sir David Lane, who is one of the best minds in the field, as chairperson of our advisory board. Under his leadership and guidance, we are confident in achieving our goal of transforming treatments for cancers that are especially prevalent in Asia where there is a high unmet need for effective therapies.”
Related Content
Aslan licences promising cancer drug from Bristol-Myers Squibb
Bristol-Myers Squibb has licensed one of its investigational oncology compounds, for the treatment of multiple …
